subcutaneous

Astellas US

Biotech

Astellas taps ReForm to improve clinical-phase biologics

The collaboration will leverage excipients ReForm developed to enable the subcutaneous and device-assisted delivery of large molecules.

Nick Paul Taylor Mar 5, 2019 9:39am

Bristol-Myers

Bristol-Myers pays Halozyme $105M to access I-O delivery tech

Sep 14, 2017 6:59am

Boxing Gloves

Omeros defends drug data, vows to unmask short seller

Aug 24, 2017 9:52am